Compelling evidence suggests that epigenetic mechanisms such as DNA methylation play a role in stress regulation and in the etiologic basis of stress related disorders such as Post traumatic Stress Disorder (PTSD). Here we describe the purpose and methods of an international consortium that was developed to study the role of epigenetics in PTSD. Inspired by the approach used in the Psychiatric Genomics Consortium, we brought together investigators representing seven cohorts with a collective sample size of N = 1147 that included detailed information on trauma exposure, PTSD symptoms, and genome-wide DNA methylation data. The objective of this consortium is to increase the analytical sample size by pooling data and combining expertise so that DNA methylation patterns associated with PTSD can be identified. Several quality control and analytical pipelines were evaluated for their control of genomic inflation and technical artifacts with a joint analysis procedure established to derive comparable data over the cohorts for meta-analysis. We propose methods to deal with ancestry population stratification and type I error inflation and discuss the advantages and disadvantages of applying robust error estimates. To evaluate our pipeline, we report results from an epigenome-wide association study (EWAS) of age, which is a well-characterized phenotype with known epigenetic associations. Overall, while EWAS are highly complex and subject to similar challenges as genome-wide association studies (GWAS), we demonstrate that an epigenetic meta-analysis with a relatively modest sample size can be wellpowered to identify epigenetic associations. Our pipeline can be used as a framework for consortium efforts for EWAS. with a 2.8-fold increase in suicidal thoughts and behaviors (Sareen, Houlahan, Cox, & Asmundson, 2005) as well as with a number of chronic medical conditions (Boscarino, 2008; Coughlin, 2011; David, Woodward, Esquenazi, & Mellman, 2004; Heppner et al., 2009; Jakovljevic et al., 2008; Kubzansky, Koenen, Jones, & Eaton, 2009; Kubzansky, Koenen, Vokonas, & Sparrow, 2007; Luft et al., 2012).
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| INTRODUCTION
Traumatic events are reported by over 70% of individuals during their lifetime (Benjet et al., 2016) . They have been associated with a number of deleterious outcomes, including posttraumatic stress disorder (PTSD), a psychiatric disorder characterized by cognitive intrusions, avoidance, negative alterations in thoughts and mood, and alterations in physiological arousal and reactivity (American Psychiatric Association, 2000) . PTSD can be severe and disabling and is often associated with a range of comorbid psychiatric conditions such as depression and substance use disorders (Brady, Killeen, Brewerton, & Lucerini, 2000; Najt, Fusar-Poli, & Brambilla, 2011) . PTSD has also been associated with a 2.8-fold increase in suicidal thoughts and behaviors (Sareen, Houlahan, Cox, & Asmundson, 2005) as well as with a number of chronic medical conditions (Boscarino, 2008; Coughlin, 2011; David, Woodward, Esquenazi, & Mellman, 2004; Heppner et al., 2009; Jakovljevic et al., 2008; Kubzansky, Koenen, Jones, & Eaton, 2009; Kubzansky, Koenen, Vokonas, & Sparrow, 2007; Luft et al., 2012) .
While the risk of developing PTSD depends in part on the nature of the trauma (Kessler, 2000) , only a minority of those exposed to trauma develop PTSD. As a result, despite the high prevalence of lifetime trauma, the overall lifetime prevalence of PTSD in the United States is 6.8%, (Breslau et al., 1998; Kessler et al., 2005; Resnick, Kilpatrick, Dansky, Saunders, & Best, 1993) , which suggests there are individual differences in resilience that, if better understood, might inform the development of new approaches to prevention and treatment.
Genetic epidemiological studies suggest that both genetic and environmental factors contribute to PTSD risk. Twin studies estimate the heritability of PTSD to be between 30% and 70%, (Sartor et al., 2012; Sartor et al., 2011; Stein, Jang, Taylor, Vernon, & Livesley, 2002; True et al., 1993; Xian et al., 2000) with the remaining variance being attributed to environmental factors. Genetic research, based on both candidate gene and genome-wide association studies (GWAS), has provided support for the role of genetics in the development and severity of PTSD and has begun to identify variants that account for some of the genetic influence on PTSD. The genetic loci identified in the extant GWAS have been implicated in a variety of processes, including neuroprotection, actin polymerization, neuronal function, and immune function (Almli et al., 2014; Guffanti et al., 2013; Logue et al., 2013; Xie et al., 2013) . Although promising, no robust genetic variants associated with PTSD have been identified and much work remains to be done to understand the biological basis of PTSD risk (Logue et al., 2015) .
A growing body of work has explored the role of environmental influences on an individual's response to trauma. Given the dependence of PTSD development on exposure to environmental (i.e., traumatic) events, clarifying the ways in which environmental influences might affect biological function are critical to understanding the etiology of PTSD. In this regard, epigenetic mechanisms, which can mediate environmental influences on gene function, are particularly relevant. Epigenetic modifications, such as DNA methylation at cytosine-guanine dinucleotides (CpG sites), induce changes in gene expression in part through structural alterations of DNA that are maintained through each round of cell division; they respond to changes in the environment, are potentially reversible, and can be targeted for disease therapies (Feinberg, 2007) . DNA methylation regulates gene expression by influencing the recruitment and binding of regulatory proteins to DNA. Typically, higher methylation at gene promoter regions correlates with decreased expression of that gene, while intragenic methylation can regulate alternative promoters and enhancers (Bonasio, Tu, & Reinberg, 2010; Maunakea et al., 2010) .
Animal studies have demonstrated that epigenetic changesparticularly alterations in DNA methylation in response to nurturingare related to altered responses to stress (Jirtle & Skinner, 2007; Weaver et al., 2004) . Similar alterations have been reported in the human literature, in both central and peripheral tissues (McGowan et al., 2009; Tyrka, Price, Marsit, Walters, & Carpenter, 2012) .
Considering the influence of traumatic stress on DNA methylation seen in some studies (Vinkers et al., 2015) , epigenetic-based investigations may extend genetic research findings. For example, research reporting an association of PTSD with a genetic variant in the PAC1 receptor (ADCYAP1R1; rs2267735) went beyond this finding to observe that PTSD severity was also correlated with methylation levels of the gene . Other work has suggested an interactive effect between trauma burden and DNA methylation in the serotonin transporter locus (SLC6A4) on PTSD risk, independent of the widely studied length polymorphism at this same locus (Koenen et al., 2011 ) and a potentially interacting effect of genetic and epigenetic variation at the dopamine receptor (SLC6A3) on PTSD risk (Chang et al., 2012) . Indeed, stress exposure itself has been shown to alter epigenetic patterns in both animal and human studies (Moser et al., 2015; Roth, Lubin, Funk, & Sweatt, 2009; Sipahi et al., 2014) . In addition to candidate gene methylation studies, a small number of studies have examined genome-wide DNA methylation patterns in PTSD (Mehta et al., 2013; Smith et al., 2011; Uddin et al., 2010) . In these first genome-wide studies of DNA methylation, immune dysregulation figured prominently among the biological networks associated with PTSD and, at a CpG site level, DNA methylation levels in several CpGs showed suggestive evidence of replication between these studies (Mehta et al., 2013; Smith et al., 2011; Uddin et al., 2010) .
Although the emerging literature on epigenetic influences on PTSD is promising, the majority of research to date has been conducted with modest sample sizes, with inherent limited statistical power. Furthermore, studies of DNA methylation have been hampered by technical issues including batch effects (Harper, Peters, & Gamble, 2013 ) and blood cell composition (Houseman et al., 2012) . Experience from large-scale genetic studies, such as the Psychiatric Genomics Consortium (PGC), underscores how large collaborative endeavors can provide the adequate sample sizes and the statistical power necessary to produce significant and replicable results (Logue et al., 2015) . Based on this experience, the PGC-PTSD formed the epigenetics working group to organize an expansive network of investigators and their collection of samples with genome-wide DNA methylation data available for joint analyses. | 621 the data from any one group. Almost universally used in current largescale genomic consortia is meta-analysis, through which the data from individual sites are analyzed separately and combined based on summary statistics. In many cases, meta-analysis of individual-level results yields results comparable to those of a "mega-analysis" of pooled data from different studies, (Lin & Zeng, 2010; Mathew & Nordstrom, 1999; Olkin & Sampson, 1998) . However, there have been important distinctions in the way the meta-analysis strategy has been implemented across consortia, including variations in the degree to which the cleaning and analysis of the individual-level data occurs (i.e., centralized vs. distributed). The analysis of individual data in a centralized manner allows a high degree of control over the quality control (QC) process and an ability to quickly perform follow-up analyses, but poses difficulties of requiring a larger degree of computational resources and storage at the consortium level and permission from all groups to share data.
The PGC-PTSD epigenetics group uses many of the same protocols and tools developed by the PGC (Logue et al., 2015) , with the difference that not all data are centrally stored and managed since some constituent samples that originate from US military, US Veteran (VA), or foreign countries are subject to additional regulatory oversight, which do not allow the sharing of individual-level genomic data. To enable participation for these studies, the PGC-PTSD epigenetics group follows a strategy similar to that of the ENIGMA consortium (Thompson et al., 2014) , in which a set of protocols and scripts are created, in this case to implement standardized QC and analysis pipelines for the Illumina HumanMethylation450 BeadChip.
These scripts are performed at each participating site and analysis results are submitted to the consortium where they are assessed, collated, and meta-analyzed. In this study, we compare the performance of two QC and two analytical pipelines to control for genomic inflation, present the final PGC-PTSD epigenetics pipeline, and assess the performance of the PGC-PTSD epigenetics pipeline in a metaanalysis of age.
| MATERIALS AND METHODS

| The PGC EWAS cohorts
The participating cohorts, presented in Table 1 , consisted of four military cohorts (MRS, PRISMO, VA-M, and VA-NCPTSD) and three civilian cohorts (DNHS, GTP, and WTC) that all measured DNA methylation (DNAm) with the Illumina HumanMethylation450k
BeadChip. Descriptions of the cohorts are in the supplemental information. Each cohort consists of PTSD cases as well as traumaexposed controls. A total of 1,147 subjects (∼50% cases) were selected for inclusion in the EWAS and were subjected to the quality control and analytical pipelines.
| Posttraumatic stress disorder assessment
Similar to other analyses conducted by the PGC-PTSD, our analysis required consistently defining and harmonizing PTSD diagnoses across cohorts that used different instruments and methods of diagnosis (Logue et al., 2015) . We used a diagnosis of current PTSD based on the diagnostic criteria defined by each cohort's principal investigator (see supplemental information). Individuals with lifetime diagnoses of PTSD but not current PTSD were excluded from analysis.
| Quality control procedures
We tested two quality control protocols: the eventually proposed PGC pipeline and a Functional Normalization (Funnorm) pipeline. In the PGC pipeline (Supplemental Figure S1 ), study investigators first conducted a visual inspection of control-probes designed to report on each step of the Infinium protocol such as bisulfite conversion and hybridization efficiency. In addition, samples with probe detection call rates <90%
and those with an average intensity value of either <50% of the experiment-wide sample mean or <2,000 arbitrary units (AU) were excluded. Probes with detection p-values > 0.001 or those based on less than three beads were set to missing as were probes that crosshybridized between autosomes and sex chromosomes (Teschendorff et al., 2013) . CpG sites with missing data for >10% of samples within cohorts were excluded from analysis. Probes containing single nucleotide polymorphisms (SNPs; based on 1000 Genomes) within 10 base pairs of the target CpG were maintained in each dataset, but flagged and tracked throughout the analysis pipeline. This decision was based on the growing recognition that sequence variants can influence DNA methylation patterns throughout the genome (Smith et al., 2014) .
Even if an associated CpG site is influenced by genetics, such as is the case for SKA2 (Boks et al., 2016; Rice et al., 2008) , maintaining such probes is informative to our overall goal of identifying genes important for PTSD (Gibbs et al., 2010; Guintivano et al., 2014; Heyn et al., 2013) .
Normalization of probe distribution and background differences between Type I and Type II probes was conducted using Beta Mixture Quantile Normalization (BMIQ) (Teschendorff et al., 2013) after background correction. We chose BMIQ after comparing distributions of BMIQ normalized Type II probes in the Detroit Neighborhood Health Study (DNHS) with the raw distributions and distributions after applying the DASEN procedure in the R package watermelon (Supplemental Figure S2) (Pidsley et al., 2013) . Following normalization, batch effect removal as implemented in the ComBat procedure of the SVA package in bioconductor was used to account for sources of technical variations including batch and positional effects, which can cause spurious associations (Johnson, Li, & Rabinovic, 2007) . Individual Briefly, raw IDATs were loaded into R and Functional Normalization applied using the default of two principal components (PCs) as covariates. The resulting normalized beta matrix was then extracted and used for analysis.
| Cellular heterogeneity
DNA methylation is known to vary by cell type which impacts the measured whole blood methylation as a result of the amalgamation of the cell type proportions in each individual's sample. To control for possible confounding by individuals' underlying cell type heterogeneity, proportions of CD8, CD4, NK, B cells, monocytes, and granulocytes were estimated using each individual's DNA methylation data, publicly available reference data (GSE36069), and the method described by Jaffe and Irizarry (2014) (Reinius et al., 2012) , based on the Houseman algorithm (Houseman et al., 2012) . CD8, CD4, NK, B cell, and monocyte cell proportions were included as covariates in our statistical analyses.
| Ancestry
Accounting for population stratification has become routine practice for genetic association studies, and most recently has also been shown to be of importance in DNA methylation studies (Barfield et al., 2014; Nielsen et al., 2010) . GWAS methods such as principal components (PCs) derived from SNPs can be incorporated into EWAS, but were not always available for all cohorts, or all samples within a cohort. An alternative based on methylation probes that proxy nearby SNPs was developed by Barfield et al. (2014) for use in European and African American subjects. Here we evaluated and extended this approach to other ancestral populations as part of the PGC-PTSD EWAS pipeline.
A subset of ancestry-diverse subjects (N = 128, including European Americans, African Americans, Latinos/Native Americans, and "others" including East Asians) from the Marine Resiliency study (MRS) were selected based on available genome-wide genotype data (Illumina HumanOmniExpressExome array) and matching Illumina 450K methylation data (Nievergelt et al., 2015) . Ancestry using GWAS data was inferred as described in Nievergelt et al. (2013) . In brief, genotypes of 1,783 ancestry-informative markers (AIMs) were used to determine a subject's ancestry at the continental level using STRUCTUREv2.3.2.1, including prior population information of the HGDP reference set (Falush, Stephens, & Pritchard, 2003; Li et al., 2008) . Based on these ancestry estimates, subjects were placed into one of four groups: European Americans, African Americans, Latinos/ Native Americans, and "Others." PCs were derived using Eigenstrat (Price et al., 2006) . Ancestry estimates using methylation data were derived using subsets of methylation probes in close proximity to SNPs identified by Barfield et al. (2014) 
| Statistical analysis
Within each cohort, logit transformed ß values (M-values) (Du et al., 2010) were modeled by linear regression as a function of PTSD, adjusting for sex, age, the estimated cell proportions, and ancestry using PCs. For cohorts with available GWAS data, the first three PCs from the GWAS were used. For cohorts without GWAS data, the method described by Barfield et al. was used to generate ancestry PCs directly from the EWAS data. Consistent with the original paper and our analysis (full results below), the second through fourth PCs were used as covariates in the model to control for ancestry. Note that while ancestry is a primary source for variation in GWAS, other potentially confounding factors such as cellular heterogeneity are a primary source for variation in EWAS data. Comparison with SNP data showed that ancestry inference is strongest when excluding EWAS-derived PC1. QQ-plots of the PTSD p-values were examined for evidence of genomic inflation due to unaccounted technical variation or other confounders. In addition, the genomic inflation factors (λ) were calculated for each study. Two adjustments were considered to improve the precision of the estimated variances. First, moderated t-statistics were calculated using the empirical Bayes method implemented in the R package limma (Smyth, 2005) . Second, HC3 robust standard errors, which have been shown to be the most effective in samples smaller than 250, were calculated using the R package sandwich (Long & Ervin, 2000; Zeileis, 2004) .
Cohort-level analysis results were combined using the inverse normal method (Marot, Foulley, Mayer, & Jaffrézic, 2009 ). Briefly, one-sided p-values for each CpG site in each study were calculated from the t-statistics. Next z-scores were calculated from the one-sided p-values and weighted by the number of subjects in each study relative to the total in the meta-analysis. Two-sided p-values of the z-score were then calculated and genomic inflation examined. Finally, p-values were adjusted for multipletesting using the False Discovery Rate (FDR) procedure at the type I error rate level of 5% (Benjamini & Hochberg, 1995) .
| Sensitivity analysis
Numerous robust associations between age and DNAm have been reported (Bocklandt et al., 2011; Hannum et al., 2013; Horvath, 2013; Horvath et al., 2012; Weidner et al., 2014 ). Because we expect that age will be associated similarly with DNAm in each cohort, we can leverage this highly reproducible relationship to evaluate the pipeline's performance. In each cohort, we modeled methylation as a function of age along with covariates for ancestry and gender (if applicable) and meta-analyzed the results as outlined above. In addition, we measured concordance between studies by estimating the correlation between the t-statistics of the age variable.
| Power
Power for EWAS is more favorable compared to GWAS as a result of the continuous nature of the DNA methylation measures, but instead suffers from poor distribution including low variances and heteroscedasticity (Du et al., 2010) . The power to detect a differentially methylated CpG site depends on the percent difference in methylation between cases and controls, the pooled variation in methylation (σ) across CpG sites, and the number of cases and controls (Liu & Hwang, 2007) . We conducted simulations to test the smallest mean difference between PTSD cases and controls we could detect based on our projected sample size and a σ = 0.43, which represents the highest variation reported in one of our cohorts, and thus a very conservative estimate (Orr & Liu, 2009 ).
3 | RESULTS
| Participating cohorts
Sample characteristics for studies that have contributed data to this first PGC-PTSD EWAS study are listed in Table 1 (N = 1,147). Three of the seven studies are composed of civilians, while the remaining studies include active duty and veteran military populations. The majority of participants, especially from the military cohorts, were male (73%) and of European American (EA) descent (56%). All participants were exposed to trauma and half of participants suffered from current PTSD (50% 
| Power
The power analysis shows that with our sample of 573 cases and 574 controls (N = 1147), we are sufficiently powered to find at least one CpG site with a mean methylation difference of 0.08 between cases and controls (Figure 1 ).
| Ancestry
We investigated the utility of DNA methylation-based ancestry estimates based on CpGs with nearby genetic variants in cis as proposed by Barfield et al. (2014) . 
| Quality control results
The number of samples and probes, not including cross-reactive probes) removed in our proposed PGC-EWAS pipeline ranged from 677 to 10,218 across studies (Supplemental Table S3 ). Figure 3 presents the genomic inflation factors from the analysis of PTSD for each individual study using two different quality control methods as well as two different analysis pipelines: (1) our proposed PGC-EWAS pipeline, described in detail in the Methods section above, as well as (2) regardless of whether empirical Bayes or HC3 standard errors were used. Using the PGC-EWAS pipeline and HC3 standard errors, six of the seven studies showed genomic deflation with (λ < 1.0), while only one study was deflated when using empirical Bayes standard errors (Supplemental Table S1 ). These results indicate that the PTSD-PGC EWAS pipeline, combined with empirical Bayes standard errors, is the preferred method for cohorts participating in our meta-analysis.
| Sensitivity analysis: Age meta-analysis results
Results for the age analysis using our pipeline and no standard error adjustment are presented in Table 2 . All studies reported numerous Table S2 ). In addition, a forest plot of the most significant CpG site representative of the FDR significant sites, shows a consistent direction of effect in each study (Supplemental Figure S4 ).
| DISCUSSION
PTSD is unique among psychiatric disorders in that its occurrence requires exposure to a significant traumatic event. With an environmental exposure embedded into the etiology of the disorder, the PTSD diagnosis affords an unusual opportunity to identify individual differences in the biological response to trauma to increase risk for, or resilience to, the disorder. Here we have introduced an international collaboration that has been established to identify epigenetic associations-specifically, DNA methylation-related to risk for, or resilience to, PTSD. We presented the development of a consistent pipeline for processing and quality-control of epigenome-wide association data comparing two quality control approaches and statistical pipelines. In our analysis of PTSD, we found that our proposed PGC-EWAS pipeline controlled for genomic inflation and deflation more consistently than Functional Normalization, regardless of the standard error correction used. In light of these findings, we encourage consortia with epigenome-wide methylation data to implement our quality control pipeline including checks for genomic inflation and strengthened associations with age before metaanalyzing across studies.
Through these collaborative efforts to analyze existing DNA methylation data from blood obtained from both military and civilian cohorts, we are poised to collectively address one of the main challenges of psychiatric genomics, namely the need for large, harmonized samples to adequately power genome-scale analyses.
The current collaborative dataset allows detection of methylation differences around seven percent, larger than most reported methylation differences, (Vinkers et al., 2015) . Additional EWAS datasets that are forthcoming will likely prove essential to detecting PTSD-associated DNA methylation differences in our planned metaanalyses. Moving forward, we anticipate that our collaborative efforts will grow to include additional cohorts from around the world; indeed, in the last year alone, several new studies have expressed interest in participating in future EWAS analyses as their data become available.
In addition to the DNA methylation analysis the close allegiance with the PGC-PTSD group has laid the foundation for integrating data from GWAS, EWAS, and gene expression/transcriptome analyses. In combination with other biological measures and coordinated neuroimaging efforts (Logue et al., 2015) that may become accessible through this collaboration, these system-wide integrations will facilitate a more complete understanding of the molecular architecture and biological underpinnings of PTSD.
The harmonization of some study characteristics paired with the demographic and clinical diversity of the samples, including the differences between military and civilian trauma, allows us the opportunity to identify DNA methylation patterns predictive for specific groups of individuals and types of trauma. This will not only provide insight into the heterogeneity of PTSD, but may also help explain mechanisms for the variation in conditional effects of different types of trauma on PTSD (Wisco et al., 2014) . Additionally, it will also provide a framework from which DNA methylation may be informative for early risk prediction and treatment stratification.
Looking ahead, we are optimistic that our PTSD EWAS collaboration will identify blood-based DNA methylation signatures that associate reliably with PTSD. Identification of robust peripheral biomarkers is an important first step and has potential for early detection and prevention. The ultimate goal is to provide new insights into the etiology of PTSD. To truly understand the mechanistic basis of PTSD, it will be critical to compare our blood-derived epigenetic biomarkers with those from other tissues, in particular brain tissue. As a first pass, DNA methylation-based biomarkers that associate with PTSD at particular CpG sites in blood can, at this time, be compared to CpG site derived from brain tissues, thanks to the Epigenomic Roadmap datasets (Bernstein et al., 2010; Kundaje et al., 2015) .
However, these comparisons will be limited to a comparison of DNA methylation levels in brain and blood in general, as the current data are not representative of PTSD. Over time, however, the development of PTSD brain biobanks of brain and other tissue types including blood cells, will help us to pinpoint whether blood-derived, DNA methylation biomarkers of PTSD reflect similar alterations in brain tissue, as recent work suggests may be possible for certain pathways (Daskalakis, Cohen, Cai, Buxbaum, & Yehuda, 2014) . Collectively, these crosstissue efforts will provide insight into the biological pathways underlying PTSD vulnerability and will ultimately facilitate new treatment and modes of prevention. 
ACKNOWLEDGMENTS
